Compound Profile · Growth Hormone
CJC-1295 + Ipamorelin
CJC-1295 paired with Ipamorelin is one of the most-studied GH secretagogue combinations in research settings, often referenced in literature on growth hormone release, sleep architecture and body composition.
Peptide Score
Evidence
Safety
Regulatory
Transparency
Quick verdict
A widely-studied research combination. Strong mechanistic plausibility, consistent reports across small studies, regulatory status remains research-only.
Reality check
What this isn't
- Not approved for human use — research-only context
- No regulator has approved human use
- Side-effect profile not fully characterised
- Educational only — not medical advice
Full CJC-1295 + Ipamorelin review
CJC-1295 is a long-acting GHRH analog. Ipamorelin is a selective GH secretagogue. Used together, they are studied for synergistic effects on pulsatile GH release.
Both compounds are research peptides — not approved as medicines for general human use.
Looking at alternatives?
Compounds with comparable research interest but different evidence, regulatory status, or risk profile.
GH Releasing
Sermorelin
Why consider it: Related research-interest profile.
View profileGH Releasing
Tesamorelin
Why consider it: Related research-interest profile.
View profileGH Secretagogue
Ipamorelin
Why consider it: Related research-interest profile.
View profile